US2019105287A1PendingUtilityA1

Liposomal Curcumin for Treatment of Cancer

70
Assignee: UNIV TEXASPriority: Sep 7, 2005Filed: Nov 30, 2018Published: Apr 11, 2019
Est. expirySep 7, 2025(expired)· nominal 20-yr term from priority
Inventors:Razelle KurzrockLan LiKapil MehtaBharat B. Aggarwal
A61K 31/12A61K 9/1272A61K 9/0019A61P 35/00A61K 9/127
70
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides a compositions and methods for the treatment of cancer, including pancreatic cancer, breast cancer and melanoma, in a human patient. The methods and compositions of the present invention employ curcumin or a curcumin analogue encapsulated in a colloidal drug delivery system, preferably a liposomal drug delivery system. Suitable colloidal drug delivery systems also include nanoparticles, nanocapsules, microparticles or block copolymer micelles. The colloidal drug delivery system encapsulating curcumin or a curcumin analogue is administered parenterally in a pharmaceutically acceptable carrier.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method for the treatment or prevention of cancer in a mammalian subject, comprising:
 a) formulation of a colloidal drug delivery system encapsulating curcumin, a curcumin analogue or a curcumin metabolite; and   b) parenteral administration of the colloidal drug delivery system to a mammalian subject in a pharmaceutically acceptable carrier.   
     
     
         2 . The method of  claim 1 , wherein the mammalian subject is a human cancer patient. 
     
     
         3 . The method of  claim 1 , wherein the active ingredient is curcumin, or a curcumin analogue. 
     
     
         4 . The method of  claim 1 , wherein the cancer is pancreatic cancer, melanoma, or a breast cancer. 
     
     
         5 . The method of  claim 1 , wherein the colloidal drug delivery system encapsulating curcumin, a curcumin analogue or a curcumin metabolite is lipid-based. 
     
     
         6 . The method of  claim 5 , wherein the lipid-based colloidal drug delivery system comprises liposomes of phosphatidylglycerols selected from at least one of:
 dilauryloylphosphatidylglycerol, dipalmitoylphosphatidylglycerol, distearoylphosphatidylglycerol, dioleoyl-phosphatidylglycerol, dimyristoylphosphatidylglycerol, palmitoyl-oleoyl-phosphatidylglycerol, dimyristoylphosphocholine, 1,2-diacyl-sn-glycero-3-[phospho-rac-(1-glycerol)], 1-acyl-2-acyl-sn-glycero-3-[phospho-rac-(1-glycerol)], 1,2-dimyristoyl-sn-glycero-3-[phospho-rac-(1-glycerol)], and phosphatidylglycerol 1,2-dipalmitoyl-sn-glycero-3-(phospho-rac-1-glycerol), 1,2-dioleoyl-sn-glycero-3-phosphocholine, or combination thereof.   
     
     
         7 . The method of  claims 1 , wherein the colloidal drug delivery system encapsulating curcumin, a curcumin analogue or a curcumin metabolite is polymer-based. 
     
     
         8 . The method of  claim 7 , wherein the polymer-based colloidal drug delivery system comprises nanoparticles or nanospheres, microparticles or microspheres, block copolymer micelles, or nanocapsules. 
     
     
         9 . The method of  claim 1 , wherein the colloidal drug delivery system encapsulates curcumin. 
     
     
         10 . The method of  claim 1 , wherein the colloidal drug delivery system encapsulates a curcumin analogue selected from the group consisting of Ar-tumerone, methylcurcumin, demethoxy curcumin, bisdemethoxycurcumin, sodium curcuminate, dibenzoylmethane, acetylcurcumin, feruloyl methane, tetrahydrocurcumin, 1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione (curcumin), 1,7-bis(piperonyl)-1,6-heptadiene-3,5-dione (piperonyl curcumin) 1,7-bis(2-hydroxy naphthyl)-1,6-heptadiene-2,5-dione (2-hydroxyl naphthyl curcumin) and 1,1-bis(phenyl)-1,3,8,10 undecatetraene-5,7-dione. 
     
     
         11 . A method for the treatment or prevention of cancer in a patient or other mammalian subject, comprising:
 a) formulation of a non-colloidal polymeric drug delivery system encapsulating curcumin, a curcumin analogue or a curcumin metabolite; and   b) parenteral administration of the polymeric drug delivery system to a cancer patient in a pharmaceutically acceptable carrier.   
     
     
         12 . The method of  claim 11 , wherein the non-colloidal polymeric drug delivery system comprises a polymeric hydrogel. 
     
     
         13 . The method of  claim 11 , wherein the non-colloidal polymeric drug delivery system comprises a polymeric film. 
     
     
         14 . A composition for the treatment or prevention of cancer in a patient or other mammalian subject comprising curcumin, a curcumin analogue or a curcumin metabolite encapsulated in a colloidal drug delivery system in suspension in a pharmaceutically acceptable carrier. 
     
     
         15 . The composition of  claim 14 , wherein the colloidal drug delivery system encapsulating curcumin, a curcumin analogue or a curcumin metabolite is lipid-based. 
     
     
         16 . The composition of  claim 15 , wherein the lipid-based colloidal drug delivery system comprises liposomes of phosphatidylglycerols selected from at least one of: dilauryloylphosphatidylglycerol, dipalmitoylphosphatidylglycerol, distearoylphosphatidylglycerol, dioleoyl-phosphatidylglycerol, dimyristoylphosphatidylglycerol, palmitoyl-oleoyl-phosphatidylglycerol, dimyristoylphosphocholine, 1,2-diacyl-sn-glycero-3-[phospho-rac-(1-glycerol)], 1-acyl-2-acyl-sn-glycero-3-[phospho-rac-(1-glycerol)], 1,2-dimyristoyl-sn-glycero-3-[phospho-rac-(1-glycerol)], and phosphatidylglycerol 1,2-dipalmitoyl-sn-glycero-3-(phospho-rac-1-glycerol), 1,2-dioleoyl-sn-glycero-3-phosphocholine, or combination thereof. 
     
     
         17 . The composition of  claim 14 , wherein the colloidal drug delivery system encapsulating curcumin, a curcumin analogue or curcumin metabolite is polymer-based, nanoparticles or nanospheres, microparticles or microspheres, block copolymer micelles, or nanocapsules. 
     
     
         18 . The composition of  claim 14 , wherein the colloidal drug delivery system encapsulating curcumin, a curcumin analogue or a curcumin metabolite is a lyophilized powder. 
     
     
         19 . The composition of  claim 14 , wherein the colloidal drug delivery system encapsulates a curcumin analogue selected from the group consisting of Ar-tumerone, methylcurcumin, demethoxy curcumin, bisdemethoxycurcumin, sodium curcuminate, dibenzoylmethane, acetylcurcumin, feruloyl methane, tetrahydrocurcumin, 1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione (curcumin), 1,7-bis(piperonyl)-1,6-heptadiene-3,5-dione (piperonyl curcumin) 1,7-bis(2-hydroxy naphthyl)-1,6-heptadiene-2,5-dione (2-hydroxyl naphthyl curcumin) and 1,1-bis(phenyl)-1,3,8,10 undecatetraene-5,7-dione. 
     
     
         20 . A composition for the treatment or prevention of cancer in a patient or other mammalian subject comprising curcumin, a curcumin analogue or a curcumin metabolite encapsulated in a liposomes of phosphatidylglycerols selected from at least one of: dilauryloylphosphatidylglycerol, dipalmitoylphosphatidylglycerol, distearoylphosphatidylglycerol, dioleoyl-phosphatidylglycerol, dimyristoylphosphatidylglycerol, palmitoyl-oleoyl-phosphatidylglycerol, dimyristoylphosphocholine, 1,2-diacyl-sn-glycero-3-[phospho-rac-(1-glycerol)], 1-acyl-2-acyl-sn-glycero-3-[phospho-rac-(1-glycerol)], 1,2-dimyristoyl-sn-glycero-3-[phospho-rac-(1-glycerol)], and phosphatidylglycerol 1,2-dipalmitoyl-sn-glycero-3-(phospho-rac-1-glycerol), 1,2-dioleoyl-sn-glycero-3-phosphocholine, or combination thereof.

Join the waitlist — get patent alerts

Track US2019105287A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.